JenaValve said this week that it tapped Victoria Carr-Brendel, former general manager of Boston Scientific‘s (NYSE:BSX) Bayer Interventional business, as its new chief executive officer. Carr-Brendel will replace Jan Keltjens, who served as interim CEO of the transcatheter aortic valve repair-focused company since January 2015. Keltjens will remain with the company as chairman of the board, JenaValve said. […]